Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 19, 2024
- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT® for patients with recurrent glioblastoma multiforme (GBM) -
Read more at globenewswire.comNASDAQ:DRTS (6/26/2025, 6:08:57 PM)
3.015
+0.02 (+0.5%)
NASDAQ:DRTSW (6/26/2025, 4:30:01 PM)
0.2498
0 (-0.04%)
Find more stocks in the Stock Screener
